Spots Global Cancer Trial Database for bone
Every month we try and update this database with for bone cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Sorafenib and Dacarbazine in Soft Tissue Sarcoma | NCT00837148 | Sarcoma Synovial Sarcom... Leiomyosarcoma Malignant Perip... | Sorafenib and D... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Mifamurtide Combined With Post-operative Chemotherapy for Newly Diagnosed High Risk Osteosarcoma Patients | NCT03643133 | Osteosarcoma | Mifamurtide EI or M-API reg... | - 50 Years | UNICANCER | |
| Study in Localized and Disseminated Ewing Sarcoma | NCT00987636 | Ewing's Sarcoma | Zoledronic acid Busulfan Treosulfan | 48 Months - 50 Years | University Hospital Muenster | |
| Study of SU11248 in Men With Advanced Prostate Cancer | NCT00299741 | Prostate Cancer | Sunitinib | 18 Years - | Massachusetts General Hospital | |
| The Effect of High Dose Simvastatine on Multiple Myeloma | NCT00281476 | Multiple Myelom... | Simvastatine | 18 Years - | Vejle Hospital | |
| Whole-body MR in Staging Bone and Soft Tissue Metastases in Breast Cancer Patients(MetaMaRBo) | NCT01291082 | Breast Cancer | 20 Years - 80 Years | Universitaire Ziekenhuizen KU Leuven | ||
| The ODYSSEY TRIAL Phase IV Trial Evaluating the Palliative Benefit of Pamidronate or Zoledronic Acid in Breast Cancer | NCT01907880 | Breast Cancer | Pamidronate Zoledronic acid placebo | 18 Years - | Ottawa Hospital Research Institute | |
| To Learn How Bone Structure and Bone Mass Change After Long-term PPI Use | NCT01306799 | Barrett's Esoph... Erosive Esophag... Gastroesophagea... | 40 Years - 75 Years | University of Pennsylvania | ||
| Chemotherapy Resistance in Osteogenic Sarcoma and Other Solid Tumors | NCT00580385 | Osteosarcoma | Tissue Procurem... | - | Memorial Sloan Kettering Cancer Center | |
| Circulating Osteocalcin-positive Cells in Breast Cancer Bone Metastasis | NCT03814811 | Breast Neoplasm... Bone Metastases | Circulating Ost... | 20 Years - | Seoul National University Hospital | |
| CANPOS: Predictive Biomarkers of Tumor Progression in Non-small Cell Lung Cancer | NCT02764606 | Non-small Cell ... | Serum and plasm... | 18 Years - 70 Years | Hospices Civils de Lyon | |
| Zoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma Participants | NCT00622505 | Multiple Myelom... | zoledronic acid | 18 Years - | Novartis | |
| Cytogenetic and Molecular Genetic Studies in Bone Sarcomas | NCT00579930 | Lung Cancer | - | Memorial Sloan Kettering Cancer Center | ||
| Dynamic Contrast Enhanced MRI(DCE-MRI)of Bone Tumors | NCT00598741 | Sarcoma Bone Tumor | DCE-MRI | - | Memorial Sloan Kettering Cancer Center | |
| Study in Localized and Disseminated Ewing Sarcoma | NCT00987636 | Ewing's Sarcoma | Zoledronic acid Busulfan Treosulfan | 48 Months - 50 Years | University Hospital Muenster | |
| Zoledronic Acid (ZOMETA) With Cyclophosphamide With Neuroblastoma and Cortical Bone Involvement | NCT00206388 | NEUROBLASTOMA | Zolendric acid Cyclophosphamid... | - 30 Years | Baylor College of Medicine | |
| The ODYSSEY TRIAL Phase IV Trial Evaluating the Palliative Benefit of Pamidronate or Zoledronic Acid in Breast Cancer | NCT01907880 | Breast Cancer | Pamidronate Zoledronic acid placebo | 18 Years - | Ottawa Hospital Research Institute | |
| Cytogenetic and Molecular Genetic Studies in Bone Sarcomas | NCT00579930 | Lung Cancer | - | Memorial Sloan Kettering Cancer Center | ||
| Chemotherapy Resistance in Osteogenic Sarcoma and Other Solid Tumors | NCT00580385 | Osteosarcoma | Tissue Procurem... | - | Memorial Sloan Kettering Cancer Center | |
| A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations | NCT05199584 | Solid Tumors Wi... | ENV-101 (talade... | 18 Years - | Endeavor Biomedicines, Inc. | |
| Safety Study of Autologous Dendritic Cells Injected Into the Prostate After Cryoablation for Advanced Prostate Cancer | NCT00753220 | Prostate Cancer | VDC2008 Cyclophosphamid... | 18 Years - | Bostwick Laboratories | |
| CANPOS: Predictive Biomarkers of Tumor Progression in Non-small Cell Lung Cancer | NCT02764606 | Non-small Cell ... | Serum and plasm... | 18 Years - 70 Years | Hospices Civils de Lyon | |
| Study of SU11248 in Men With Advanced Prostate Cancer | NCT00299741 | Prostate Cancer | Sunitinib | 18 Years - | Massachusetts General Hospital | |
| Tranexamic Acid After Pathological Fracture Treated With Modular Arthroplasty | NCT06244498 | Metastases to B... | Tranexamic acid... | - | Podkarpackie Oncological Center | |
| Zoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma Participants | NCT00622505 | Multiple Myelom... | zoledronic acid | 18 Years - | Novartis |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
